UniProt ID | PSA5_HUMAN | |
---|---|---|
UniProt AC | P28066 | |
Protein Name | Proteasome subunit alpha type-5 | |
Gene Name | PSMA5 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 241 | |
Subcellular Localization | Cytoplasm . Nucleus . | |
Protein Description | Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex).. | |
Protein Sequence | MFLTRSEYDRGVNTFSPEGRLFQVEYAIEAIKLGSTAIGIQTSEGVCLAVEKRITSPLMEPSSIEKIVEIDAHIGCAMSGLIADAKTLIDKARVETQNHWFTYNETMTVESVTQAVSNLALQFGEEDADPGAMSRPFGVALLFGGVDEKGPQLFHMDPSGTFVQCDARAIGSASEGAQSSLQEVYHKSMTLKEAIKSSLIILKQVMEEKLNATNIELATVQPGQNFHMFTKEELEEVIKDI | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
1 | Acetylation | -------MFLTRSEY -------CCCCHHHC | 5.84 | - | |
6 | Phosphorylation | --MFLTRSEYDRGVN --CCCCHHHCCCCCC | 34.96 | 21945579 | |
8 | Phosphorylation | MFLTRSEYDRGVNTF CCCCHHHCCCCCCCC | 16.52 | 21945579 | |
10 | Methylation | LTRSEYDRGVNTFSP CCHHHCCCCCCCCCC | 50.48 | 115489329 | |
14 | Phosphorylation | EYDRGVNTFSPEGRL HCCCCCCCCCCCCCE | 24.08 | 21945579 | |
16 | Phosphorylation | DRGVNTFSPEGRLFQ CCCCCCCCCCCCEEE | 21.72 | 29255136 | |
20 | Methylation | NTFSPEGRLFQVEYA CCCCCCCCEEEHHHH | 30.57 | 115489321 | |
26 | Phosphorylation | GRLFQVEYAIEAIKL CCEEEHHHHHHHHHC | 17.64 | 28796482 | |
36 | Phosphorylation | EAIKLGSTAIGIQTS HHHHCCCEEEEEECC | 22.09 | - | |
43 | Phosphorylation | TAIGIQTSEGVCLAV EEEEEECCCCEEEEE | 18.91 | - | |
52 | Ubiquitination | GVCLAVEKRITSPLM CEEEEEEECCCCCCC | 42.37 | - | |
55 | Phosphorylation | LAVEKRITSPLMEPS EEEEECCCCCCCCCC | 28.46 | 23927012 | |
56 | Phosphorylation | AVEKRITSPLMEPSS EEEECCCCCCCCCCH | 17.42 | 19664994 | |
59 | Sulfoxidation | KRITSPLMEPSSIEK ECCCCCCCCCCHHHH | 8.92 | 21406390 | |
62 | Phosphorylation | TSPLMEPSSIEKIVE CCCCCCCCHHHHHHE | 30.55 | 30266825 | |
63 | Phosphorylation | SPLMEPSSIEKIVEI CCCCCCCHHHHHHEE | 45.54 | 30266825 | |
66 | Ubiquitination | MEPSSIEKIVEIDAH CCCCHHHHHHEECHH | 50.83 | - | |
79 | Phosphorylation | AHIGCAMSGLIADAK HHHHHHHHHHHHCHH | 16.36 | - | |
86 | Ubiquitination | SGLIADAKTLIDKAR HHHHHCHHHHHHHHH | 44.40 | 21890473 | |
91 | Acetylation | DAKTLIDKARVETQN CHHHHHHHHHHEEEC | 30.97 | 23749302 | |
91 | Ubiquitination | DAKTLIDKARVETQN CHHHHHHHHHHEEEC | 30.97 | - | |
91 | Malonylation | DAKTLIDKARVETQN CHHHHHHHHHHEEEC | 30.97 | 26320211 | |
149 | Ubiquitination | LFGGVDEKGPQLFHM EECCCCCCCCCCEEE | 72.00 | - | |
149 | Sumoylation | LFGGVDEKGPQLFHM EECCCCCCCCCCEEE | 72.00 | - | |
156 | Sulfoxidation | KGPQLFHMDPSGTFV CCCCCEEECCCCCEE | 6.76 | 30846556 | |
159 | Phosphorylation | QLFHMDPSGTFVQCD CCEEECCCCCEEEEC | 46.32 | 30622161 | |
161 | Phosphorylation | FHMDPSGTFVQCDAR EEECCCCCEEEECCE | 25.60 | 30622161 | |
172 | Phosphorylation | CDARAIGSASEGAQS ECCEEECCCCCHHHH | 23.62 | 28258704 | |
174 | Phosphorylation | ARAIGSASEGAQSSL CEEECCCCCHHHHHH | 37.96 | - | |
179 | Phosphorylation | SASEGAQSSLQEVYH CCCCHHHHHHHHHHH | 32.27 | 23186163 | |
180 | Phosphorylation | ASEGAQSSLQEVYHK CCCHHHHHHHHHHHH | 23.22 | 23186163 | |
185 | Phosphorylation | QSSLQEVYHKSMTLK HHHHHHHHHHCCCHH | 11.63 | 28152594 | |
187 | Acetylation | SLQEVYHKSMTLKEA HHHHHHHHCCCHHHH | 25.00 | 25953088 | |
187 | Ubiquitination | SLQEVYHKSMTLKEA HHHHHHHHCCCHHHH | 25.00 | 21890473 | |
187 | Ubiquitination | SLQEVYHKSMTLKEA HHHHHHHHCCCHHHH | 25.00 | 21890473 | |
192 | Succinylation | YHKSMTLKEAIKSSL HHHCCCHHHHHHHHH | 35.61 | 23954790 | |
192 | Ubiquitination | YHKSMTLKEAIKSSL HHHCCCHHHHHHHHH | 35.61 | 21890473 | |
192 | 2-Hydroxyisobutyrylation | YHKSMTLKEAIKSSL HHHCCCHHHHHHHHH | 35.61 | - | |
192 | Sumoylation | YHKSMTLKEAIKSSL HHHCCCHHHHHHHHH | 35.61 | - | |
192 | Ubiquitination | YHKSMTLKEAIKSSL HHHCCCHHHHHHHHH | 35.61 | 21890473 | |
192 | Sumoylation | YHKSMTLKEAIKSSL HHHCCCHHHHHHHHH | 35.61 | - | |
196 | Ubiquitination | MTLKEAIKSSLIILK CCHHHHHHHHHHHHH | 40.83 | 21890473 | |
196 | 2-Hydroxyisobutyrylation | MTLKEAIKSSLIILK CCHHHHHHHHHHHHH | 40.83 | - | |
196 | Sumoylation | MTLKEAIKSSLIILK CCHHHHHHHHHHHHH | 40.83 | - | |
196 | Acetylation | MTLKEAIKSSLIILK CCHHHHHHHHHHHHH | 40.83 | 25953088 | |
196 | Ubiquitination | MTLKEAIKSSLIILK CCHHHHHHHHHHHHH | 40.83 | 21890473 | |
196 | Sumoylation | MTLKEAIKSSLIILK CCHHHHHHHHHHHHH | 40.83 | - | |
198 | O-linked_Glycosylation | LKEAIKSSLIILKQV HHHHHHHHHHHHHHH | 20.70 | 23301498 | |
203 | Sumoylation | KSSLIILKQVMEEKL HHHHHHHHHHHHHHH | 30.36 | - | |
203 | Acetylation | KSSLIILKQVMEEKL HHHHHHHHHHHHHHH | 30.36 | 25038526 | |
203 | Ubiquitination | KSSLIILKQVMEEKL HHHHHHHHHHHHHHH | 30.36 | 21890473 | |
203 | Sumoylation | KSSLIILKQVMEEKL HHHHHHHHHHHHHHH | 30.36 | - | |
203 | 2-Hydroxyisobutyrylation | KSSLIILKQVMEEKL HHHHHHHHHHHHHHH | 30.36 | - | |
209 | Ubiquitination | LKQVMEEKLNATNIE HHHHHHHHHCCCCEE | 33.46 | 21890473 | |
209 | Acetylation | LKQVMEEKLNATNIE HHHHHHHHHCCCCEE | 33.46 | 23954790 | |
213 | Phosphorylation | MEEKLNATNIELATV HHHHHCCCCEEEEEE | 35.34 | 30622161 | |
219 | Phosphorylation | ATNIELATVQPGQNF CCCEEEEEECCCCCE | 32.09 | 30622161 | |
228 | Sulfoxidation | QPGQNFHMFTKEELE CCCCCEECEEHHHHH | 3.90 | 21406390 | |
230 | Phosphorylation | GQNFHMFTKEELEEV CCCEECEEHHHHHHH | 29.94 | 30622161 | |
231 | Sumoylation | QNFHMFTKEELEEVI CCEECEEHHHHHHHH | 37.62 | - | |
231 | Ubiquitination | QNFHMFTKEELEEVI CCEECEEHHHHHHHH | 37.62 | 21890473 | |
239 | Ubiquitination | EELEEVIKDI----- HHHHHHHHCC----- | 55.32 | - | |
239 | Acetylation | EELEEVIKDI----- HHHHHHHHCC----- | 55.32 | 26822725 | |
239 | Succinylation | EELEEVIKDI----- HHHHHHHHCC----- | 55.32 | 23954790 |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of PSA5_HUMAN !! |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of PSA5_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of PSA5_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Mass spectrometric characterization of the affinity-purified human26S proteasome complex."; Wang X., Chen C.-F., Baker P.R., Chen P.-L., Kaiser P., Huang L.; Biochemistry 46:3553-3565(2007). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND MASS SPECTROMETRY. | |
Phosphorylation | |
Reference | PubMed |
"Quantitative phosphoproteomic analysis of T cell receptor signalingreveals system-wide modulation of protein-protein interactions."; Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,Rodionov V., Han D.K.; Sci. Signal. 2:RA46-RA46(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-16, AND MASSSPECTROMETRY. | |
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-16; THR-55 AND SER-56,AND MASS SPECTROMETRY. | |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-16 AND THR-55, AND MASSSPECTROMETRY. | |
"Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-16 AND SER-56, AND MASSSPECTROMETRY. | |
"Improved titanium dioxide enrichment of phosphopeptides from HeLacells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra."; Yu L.-R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.; J. Proteome Res. 6:4150-4162(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-16, AND MASSSPECTROMETRY. | |
"A probability-based approach for high-throughput proteinphosphorylation analysis and site localization."; Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; Nat. Biotechnol. 24:1285-1292(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-16, AND MASSSPECTROMETRY. | |
"Large-scale characterization of HeLa cell nuclear phosphoproteins."; Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,Li J., Cohn M.A., Cantley L.C., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-56, AND MASSSPECTROMETRY. |